Specialized Migraine Treatment Solutions for Unique Environments

Publication ID: 24-11857542_0009_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Specialized Migraine Treatment Solutions for Unique Environments,” Published Technical Disclosure No. 24-11857542_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857542_0009_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,542.

Summary of the Inventive Concept

The present disclosure relates to specialized medicaments and methods for treating migraine in unique operational environments, such as high-altitude, air travel, remote wilderness, high-security, and disaster relief settings.

Background and Problem Solved

The original patent addressed the unmet need for effective treatments of migraine with or without aura. However, it did not consider the specific challenges posed by treating migraine in unique operational environments. The present inventive concept adapts the original patent's approach to address these specific challenges, ensuring effective treatment in diverse settings.

Detailed Description of the Inventive Concept

The inventive concept comprises specialized systems, methods, and kits for treating migraine in unique operational environments. For example, the system for treating migraine in a high-altitude environment includes a portable storage unit containing a predetermined quantity of ubrogepant, designed to operate at elevations above 8,000 feet. Similarly, the method for treating migraine in a patient undergoing air travel involves orally administering 50 mg of ubrogepant to the patient prior to takeoff, ensuring alleviation of migraine symptoms during the flight. Other embodiments include kits for treating migraine in remote wilderness settings and systems for treating migraine in high-security environments.

Novelty and Inventive Step

The inventive concept's novelty lies in its adaptation of the original patent's approach to address the specific challenges posed by unique operational environments. The inventive step resides in the recognition of the need for specialized solutions and the development of systems, methods, and kits that effectively treat migraine in these environments.

Alternative Embodiments and Variations

Alternative embodiments may include systems and methods for treating migraine in other unique environments, such as space travel or extreme weather conditions. Variations may also include different dosing regimens or formulations of ubrogepant tailored to specific environments.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the areas of migraine treatment and emergency response. Target industries may include aerospace, defense, and disaster relief organizations, as well as remote wilderness adventure and tourism operators.

Field of Art

Pharmaceutical treatment of neurological conditions, specifically migraine management, with expertise in drug dosing, patient-specific administration, and specialized medical interventions

Person of Ordinary Skill (PHOSITA) Profile

A medical researcher or clinical pharmacologist with advanced training in neuropharmacology, experienced in developing targeted drug delivery solutions for complex medical conditions, familiar with patient-specific dosing adaptations

Obviousness Rationale

A PHOSITA would recognize that the core ubrogepant treatment method from the source patent can be readily adapted to unique environmental contexts by applying standard pharmaceutical engineering principles. The fundamental pharmacological mechanism remains consistent across different operational scenarios. The variations represent predictable extensions of the original treatment approach, utilizing known drug administration techniques.

Obvious Combinations & Variations

Source Patent Element
Oral administration of 50 mg ubrogepant for migraine treatment
PTD Variation
Specialized portable storage units for ubrogepant in high-altitude or high-security environments
Obviousness Reasoning
A PHOSITA would find it obvious to develop specialized storage solutions that maintain drug integrity, using standard pharmaceutical packaging techniques known in the field
Source Patent Element
Method of treating migraine with specific dosing parameters
PTD Variation
Adapting ubrogepant administration for air travel and disaster relief scenarios
Obviousness Reasoning
Modifying drug administration protocols for specific environmental conditions represents a predictable design choice using known medical intervention strategies
Source Patent Element
Treatment method for patients with specific physiological conditions
PTD Variation
Creating specialized migraine treatment kits for remote wilderness settings
Obviousness Reasoning
Developing context-specific medical intervention kits is a standard approach in pharmaceutical field, representing an obvious combination of known treatment principles
Source Patent Element
Oral administration of 50 mg ubrogepant dose
PTD Variation
Tailored dosing for unique operational environments like high-altitude or air travel
Obviousness Reasoning
Adjusting pharmaceutical interventions for specific environmental stressors is a predictable extension of standard medical practice
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857542, a person having ordinary skill in the art would find the variations disclosed herein to be obvious modifications of the existing migraine treatment method. The proposed adaptations represent predictable extensions of known pharmaceutical intervention strategies, utilizing standard techniques for drug administration and environmental adaptation, and therefore would be considered obvious to a skilled practitioner in the field.

Original Patent Information

Patent NumberUS 11,857,542
TitleTreatment of migraine
Assignee(s)Allergan Pharmaceuticals International Limited